Figure 1. Enrollment and outcomes.

91 AML patients were treated with decitabine for 5 consecutive days (day 1-5) and G-CSF (day 0-9) for priming combined with cytarabine (day 3-9), aclarubicin for 4 days (day 3-6) (D-CAG). Up to two cycles of induction therapy were allowed if response was not achieved. Patients who achieved CR accepted the next cycle treatment for recovery of hematopoiesis and resolution of all toxicities. Patients who did not achieve CR or PR after the second cycle of induction therapy were offered alternative therapies. Post-remission therapy consisted of 4-6 cycles. Treatment was continued until relapse or progressive disease, death, or unacceptable toxicity occurred, or patients/physicians requested the discontinuity.